Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Deferred Revenue (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Current Deferred Revenue for 12 consecutive years, with $27.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue fell 78.46% year-over-year to $27.9 million, compared with a TTM value of $27.9 million through Sep 2025, down 78.46%, and an annual FY2024 reading of $67.2 million, down 68.35% over the prior year.
  • Current Deferred Revenue was $27.9 million for Q3 2025 at CytomX Therapeutics, up from $11.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $301.3 million in Q4 2022 and bottomed at $4.0 million in Q1 2023.
  • Average Current Deferred Revenue over 5 years is $150.0 million, with a median of $160.5 million recorded in 2024.
  • The sharpest move saw Current Deferred Revenue plummeted 98.55% in 2023, then soared 4484.28% in 2024.
  • Year by year, Current Deferred Revenue stood at $284.8 million in 2021, then rose by 5.82% to $301.3 million in 2022, then fell by 29.54% to $212.3 million in 2023, then tumbled by 68.35% to $67.2 million in 2024, then crashed by 58.46% to $27.9 million in 2025.
  • Business Quant data shows Current Deferred Revenue for CTMX at $27.9 million in Q3 2025, $11.6 million in Q2 2025, and $49.4 million in Q1 2025.